HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a randomized, 2-arm, open-label, multicenter, international phase II trial. A total of 196 patients will be included. The study will include patients with metastatic Hormone Receptor positive / Human Epidermal Growth Factor Receptor (HER2) negative breast cancer with progressive disease after endocrine treatment. Patients will be randomized (1:1) between two treatment arms: A. palbociclib + fulvestrant and b. capecitabine.
Epistemonikos ID: b462fbd980130cdd3c757f79030b450b7885f1b5
First added on: May 21, 2024